公开(公告)号：US20250057887A1

公开(公告)日：2025-02-20

申请号：US18938873

申请日：2024-11-06

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Clive Svendsen ,  Dhruv Sareen

IPC: A61K35/39 ,  C12N5/071

Abstract: Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

公开(公告)号：US20250043246A1

公开(公告)日：2025-02-06

申请号：US18926918

申请日：2024-10-25

Applicant: Novo Nordisk A/S

Inventor： Jeannette Schlichting Kirkegaard

IPC: C12N5/071 ,  A01N1/02 ,  A61K35/39

Abstract: The present invention relates to method of enriching NKX6.1 and C-peptide co-expressing cell aggregates derived in vitro from stem cells said method comprising the steps of dissociating the endocrine cell aggregates into single cells, treating the single cells with cryopreservation medium and lowering temperature to obtain cryopreserved cells, thawing the cryopreserved cells; and re-aggregating the cells obtained after thawing into endocrine cells.

公开(公告)号：US12173324B2

公开(公告)日：2024-12-24

申请号：US17988257

申请日：2022-11-16

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： George Harb ,  Chunhui Xie

IPC: C12N5/071 ,  A61K35/39

Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

公开(公告)号：US12097223B2

公开(公告)日：2024-09-24

申请号：US17022807

申请日：2020-09-16

Applicant: Astellas Institute for Regenerative Medicine

Inventor： Erin Anne Kimbrel ,  Robert P. Lanza ,  Jianlin Chu ,  Nicholas Arthur Kouris

IPC: C12N5/0775 ,  A61F2/14 ,  A61F9/08 ,  A61K35/28 ,  A61K35/30 ,  A61K35/34 ,  A61K35/36 ,  A61K35/39 ,  A61K35/407 ,  C12N5/071 ,  C12N5/0789 ,  G06F9/54

CPC classification number: A61K35/28 ,  A61F2/141 ,  A61F9/08 ,  A61K35/30 ,  A61K35/34 ,  A61K35/36 ,  A61K35/39 ,  A61K35/407 ,  C12N5/0647 ,  C12N5/0662 ,  C12N5/0668 ,  C12N5/0692 ,  G06F9/542 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/26 ,  C12N2502/1171 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/28 ,  C12N2533/54 ,  G06F2218/00 ,  A61K35/30 ,  A61K2300/00 ,  A61K35/34 ,  A61K2300/00 ,  A61K35/36 ,  A61K2300/00 ,  A61K35/39 ,  A61K2300/00 ,  A61K35/407 ,  A61K2300/00 ,  A61K35/28 ,  A61K2300/00

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

公开(公告)号：US12066431B2

公开(公告)日：2024-08-20

申请号：US17201036

申请日：2021-03-15

Applicant: Accelerated Biosciences Corp.

Inventor： Jau-Nan Lee ,  Tony Tung-Ying Lee ,  Yuta Lee

IPC: G01N33/50 ,  A61K35/39 ,  A61K35/54 ,  A61K39/395 ,  C12N5/071 ,  C12N5/073 ,  C12N5/0735 ,  A61K35/12

CPC classification number: G01N33/5073 ,  A61K35/39 ,  A61K35/54 ,  A61K39/395 ,  C12N5/0605 ,  C12N5/0606 ,  C12N5/0677 ,  A61K35/12 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2501/115 ,  C12N2506/02 ,  C12N2533/54

Abstract: Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.

公开(公告)号：US20240269194A1

公开(公告)日：2024-08-15

申请号：US18567094

申请日：2022-06-09

Applicant: City of Hope

Inventor： Fouad Kandeel

IPC: A61K35/39 ,  A61K9/00 ,  A61K31/4439 ,  A61K31/4985 ,  A61K38/22 ,  A61P3/10 ,  C12N5/071

CPC classification number: A61K35/39 ,  A61K9/0019 ,  A61K31/4439 ,  A61K31/4985 ,  A61K38/2207 ,  A61P3/10 ,  C12N5/0676

Abstract: Provided herein, inter alia, are compositions and methods for treating diabetes in a subject in need thereof. The methods include administering to the subject gastrin-treated islet cells.

公开(公告)号：US12049646B2

公开(公告)日：2024-07-30

申请号：US18395362

申请日：2023-12-22

Applicant: President and Fellows of Harvard College

Inventor： Quinn P. Peterson ,  Felicia J. Pagliuca ,  Douglas A. Melton ,  Jeffrey Robert Millman ,  Michael Saris Segel ,  Mads Gurtler

IPC: C12N5/071 ,  A61K35/39 ,  A61P3/10 ,  A61P5/48 ,  A61P5/50 ,  C12N5/0735 ,  C12N5/074

CPC classification number: C12N5/0678 ,  A61K35/39 ,  A61P3/10 ,  A61P5/48 ,  A61P5/50 ,  C12N5/0606 ,  C12N5/0676 ,  C12N5/0696 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/15 ,  C12N2501/16 ,  C12N2501/375 ,  C12N2501/385 ,  C12N2501/395 ,  C12N2501/40 ,  C12N2501/41 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/22 ,  C12N2506/45

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

公开(公告)号：US20240245733A1

公开(公告)日：2024-07-25

申请号：US18435722

申请日：2024-02-07

Applicant: The Regents of the University of California ,  U.S. Govenment Represented by the Department of Veterans Affairs

Inventor： Casey Ward ,  Qizhi TANG ,  Peter STOCK ,  Gaetano FALEO ,  Gopika NAIR ,  Matthias HEBROK ,  Wenhan CHANG ,  Thuy VO ,  Jeffrey A. BLUESTONE ,  Elenora DE KLERK

IPC: A61K35/55 ,  A61K9/00 ,  A61K35/39 ,  A61P3/10 ,  C12N5/071

CPC classification number: A61K35/55 ,  A61K9/0019 ,  A61K9/0024 ,  A61K35/39 ,  A61P3/10 ,  C12N5/0617 ,  C12N5/0676 ,  A61K2300/00 ,  C12N2506/02 ,  C12N2506/078

Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

公开(公告)号：US20240207325A1

公开(公告)日：2024-06-27

申请号：US18554136

申请日：2022-04-08

Applicant: BIOCRINE AB

Inventor： Per-Olof Berggren ,  Ingo Leibiger ,  Barbara Leibiger

IPC: A61K35/39 ,  A61K38/22 ,  A61K38/26 ,  A61P3/04 ,  C07K14/575 ,  C07K14/605 ,  C12N5/071 ,  C12N15/86

CPC classification number: A61K35/39 ,  A61K38/2264 ,  A61K38/26 ,  A61P3/04 ,  C07K14/5759 ,  C07K14/605 ,  C12N5/0677 ,  C12N15/86 ,  C12N2533/50 ,  C12N2710/10043

Abstract: Engineered pancreatic islet organoids encoding a polypeptide not endogenously expressed in pancreatic islet cells and methods for using them to treat diseases and disorders associated with reduced or absent expression of the polypeptide are provided.

公开(公告)号：US20240189365A1

公开(公告)日：2024-06-13

申请号：US18286955

申请日：2022-04-14

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Christopher BURLAK

IPC: A61K35/407 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/42 ,  A61K35/55 ,  A61P37/06 ,  C12N5/071

CPC classification number: A61K35/407 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/42 ,  A61K35/55 ,  A61P37/06 ,  C12N5/0676 ,  C12N2510/00

Abstract: Provided herein are genetically modified porcine cells comprising a reduced or eliminated level of β1,3-N-acetylglucosaminyltransferase 5 (B3gnt5) activity as compared to a normal porcine cell, and methods of improving a rejection related symptom by transplanting porcine cells, tissues or organs to a subject in need thereof.